Prostate cancer and supplementation with α-tocopherol and β-carotene:: Incidence and mortality in a controlled trial
Prostate cancer and supplementation with α-tocopherol and β-carotene:: Incidence and mortality in a controlled trial
复制标题
DOI：
10.1093/jnci/90.6.440
复制
发表时间：
1998-03-18
期刊：
影响因子：
--
通讯作者：
Edwards, BK
中科院分区：
文献类型：
--
作者：
Heinonen, OP;Albanes, D;Edwards, BK
背景：流行病学研究表明，维生素 E 和 β-胡萝卜素可能各自影响前列腺癌的发展。在一项对照试验“α-生育酚、β-胡萝卜素癌症预防研究”中，我们研究了单独或一起补充 α-生育酚（维生素 E 的一种形式）和 β-胡萝卜素对男性吸烟者前列腺癌的影响。方法：总共 29133 名来自西南地区、年龄 50-69 岁的男性吸烟者芬兰被随机分配每天接受 α-生育酚（50 毫克）、β-胡萝卜素（20 毫克），两种药物或安慰剂，持续 5-8 Sears（中位数，6.1 年），通过比例风险模型估计补充效果，并计算双侧 P 值，结果：我们发现在随访期间新增 246 例前列腺癌病例，62 例死亡，下降 32%（95% 置信区间）与未接受α-生育酚的受试者(n = 14569)相比，接受α-生育酚的受试者(n = 14564)的前列腺癌发病率[CI] = -47%至-12%)，临床前列腺癌的降低很明显，但潜伏性癌症则不然。接受α-生育酚的男性中前列腺癌的死亡率降低了41%(95% CI = -65%至-1%)。与未接受β-胡萝卜素的受试者（n = 14 573）相比，接受β-胡萝卜素的受试者（n = 14560）中，前列腺癌发病率高出23%（95% CI = -4%-59%），死亡率高出15%（95% CI = -30%-89%），两种药物对诊断和死亡之间的时间间隔没有任何影响，结论：长期补充α-生育酚可显着减少前列腺癌的发生男性吸烟者的发病率和死亡率，需要其他对照试验来证实这些发现。
Background: Epidemiologic studies ha,le suggested that vitamin E and beta-carotene may each influence the development of prostate cancer, In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a controlled trial, we studied the effect of alpha-tocopherol (a form of vitamin E) and beta-carotene supplementation, separately or together, on prostate cancer in male smokers, Methods: A total of 29133 male smokers aged 50-69 years from southwestern Finland were randomly assigned to receive alpha-tocopherol (50 mg), beta-carotene (20 mg), both agents, or placebo daily for 5-8 Sears (median, 6.1 years), The supplementation effects were estimated by a proportional hazards model, and two-sided P values were calculated, Results: We found 246 new cases of and 62. deaths from prostate cancer during the follow-up period, A 32% decrease (95% confidence interval [CI] = -47% to -12%) in the incidence of prostate cancer was observed among the subjects receiving alpha-tocopherol (n = 14564) compared with those not receiving it (n = 14569), The reduction was evident in clinical prostate cancer but not in latent cancer, Mortality from prostate cancer was 41% lower (95% CI = -65% to -1%) among men receiving alpha-tocopherol. Among subjects receiving beta-carotene (n = 14560), prostate cancer incidence was 23% higher (95% CI = -4%-59%) and mortality was 15% higher (95% CI = -30%-89%) compared with those not receiving it (n = 14 573), Neither agent had any effect on the time interval between diagnosis and death, Conclusions: Long-term supplementation with alpha-tocopherol substantially reduced prostate cancer incidence and mortality in male smokers, Other controlled trials are required to confirm the findings.